AMENDMENTS TO THE CLAIMS

1. (Previously presented) A compound of the **general formula I**,



General Formula I

wherein

R^1 represents lower alkyl-O–$(CH_2)_n$-, cycloalkyl-O-$(CH_2)_n$-, cycloalkyl-CH_2-O-$(CH_2)_n$-;

R^2 represents -CH_3; R^a-Y-$(CH_2)_m$-;

R^3 represents aryl; heteroaryl;

R^4 represents hydrogen; trifluoromethyl; lower alkyl; lower alkyl-amino; lower alkyloxy; lower alkyloxy-lower alkyloxy; hydroxy-lower alkyloxy; lower alkyl-sulfinyl; lower alkylthio; lower alkylthio-lower alkyl; hydroxy-lower alkyl; lower alkyloxy-lower alkyl; hydroxy-lower alkyloxy-lower alkyl; hydroxy-lower alkyl-amino; lower alkylamino-lower alkyl; amino; di-lower alkylamino; [N-(hydroxy-lower alkyl)-N-(lower alkyl)]-amino; aryl; arylamino; aryl-lower alkylamino; aryl-thio; aryl-lower alkylthio; aryloxy; aryl-lower alkyloxy; aryl-lower alkyl; arylsulfinyl; heteroaryl; heteroaryl-oxy; heteroarylamino; heteroarylthio; heteroaryl-lower alkyl; heteroarylsulfinyl; heterocyclyl; heterocyclyl-lower alkyloxy; heterocyclyloxy; heterocyclylamino; heterocyclyl-lower alkylamino;

heterocyclylthio; heterocyclyl-lower alkylthio; heterocyclyl-lower alkyl; heterocyclylsulfinyl; cycloalkyl; cycloalkyloxy; cycloalkyl-lower alkyloxy; cycloalkylamino; cycloalkyl-lower alkylamino; cycloalkylthio; cycloalkyl-lower alkylthio; cycloalkyl-lower alkyl; cycloalkylsulfinyl;

R^6 represents hydrogen or methyl;

X represents oxygen; sulfur; $-CH_2-$ or a bond;

Y represents a bond, -O-; -NH-; $-SO_2-NH-$; $-NH-SO_2-NH-$; -O-CO-; -CO-O-; -O-CO-NH-; -NH-CO-O-; -NH-CO-NH-;

n represents the integers 2, 3, or 4;

m represents the integers 2, 3, or 4; and

R^a represents aryl, heteroaryl, lower alkyl, cycloalkyl, hydrogen;

and optically pure enantiomers, mixtures of enantiomers, optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

2. (Previously presented) The compound of claim 1, wherein R^3 represents phenyl, mono- or di-substituted phenyl substituted with ethoxy, methoxy or chlorine and **X** represents oxygen, and pharmaceutically acceptable salts thereof.

3. (Previously presented) The compound of claim 1, wherein R^3 represents phenyl, mono- or di-substituted phenyl substituted with ethoxy, methoxy or chlorine, **X** represents oxygen and R^2 represents $-(CH_2)_m-Y-R^a$, and pharmaceutically acceptable salts thereof.

4. (Previously presented) The compound of claim 1, wherein R^3 represents phenyl, mono- or di-substituted phenyl substituted with ethoxy, methoxy or chlorine, **X** represents

oxygen and R^2 represents $-(CH_2)_2$-O-R^a, with R^a being heteroaryl, and pharmaceutically acceptable salts thereof.

5. (Previously presented) The compound of claim 1, said compound having **formula II**



Formula II

and pharmaceutically acceptable salts of the compound.

6. (Previously presented) The compound of claim 1, said compound having **formula III**



Formula III

wherein **A** represents hydrogen, methyl, ethyl, chlorine, bromine, fluorine, trifluoromethyl or methoxy, and pharmaceutically acceptable salts of the compound.

7. (Previously presented) The compound of claim 1, said compound having **formula IV**



Formula IV

wherein **A** represents hydrogen, methyl, ethyl, chlorine, bromine, fluorine, trifluoromethyl or methoxy, and R^5 represents aryl or heteroaryl, and pharmaceutically acceptable salts of the compound.

8. (Previously presented) The compound of claim 1, said compound having **formula V**



Formula V

wherein **A** represents hydrogen, methyl, ethyl, chlorine, bromine, fluorine, trifluoromethyl or methoxy and R^5 represents aryl or heteroaryl, and pharmaceutically acceptable salts of the compound.

9. (Previously presented) The compound of claim 8, wherein R^5 represents a substituted pyrimidine, and pharmaceutically acceptable salts of the compound.

10. (Previously presented) The compound of claim 1, wherein R^1 represents CH_3-O-CH_2CH_2-, and R^6 represents and pharmaceutically acceptable salts of the compound.

11. (Previously presented) The compound of claim 8, wherein R^1 represents CH_3-O-CH_2CH_2-, and pharmaceutically acceptable salts of the compound.

12. (Previously presented) A compound selected from the group consisting of:

2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

2-Methoxy-ethanesulfamic acid {5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;

2-Methoxy-ethanesulfamic acid {5-(4-bromophenyl)-6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide; and

2-Methoxy-ethanesulfamic acid {5-(4-bromophenyl)-6-[2-(5-methoxypyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide.

Claims 13 – 27. (Cancelled)

28. (Previously presented) A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

Claims 29 – 34. (Cancelled)